Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy?
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single
PDF) Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
The prognostic and predictive value of serum CA19.9 in pancreatic cancer - ScienceDirect
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
CA 19-9 – Pancreatic Cancer Action Network
Cancers | Free Full-Text | Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in Gastrointestinal Cancers: Biological Rationale towards a Personalized Clinical Application
Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single
The significance of elevated tumor markers among patients with interstitial lung diseases | Scientific Reports
Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer - Yang - Journal of Gastrointestinal Oncology
CA 19-9 tumor marker | pancreatic cancer diagnosis | tumor marker (Everything you need to know) - YouTube
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study | World Journal of Surgical Oncology | Full Text
Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
Patients with normal‑range CA19‑9 levels represent a distinct subgroup of pancreatic cancer patients
![PDF] Increased CA 19-9 level in patients without malignant disease | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/26d5394683ead29cd4fea31dc58ad39515b843a6/3-Table1-1.png "PDF] Increased CA 19-9 level in patients without malignant disease | Semantic Scholar")
PDF] Increased CA 19-9 level in patients without malignant disease | Semantic Scholar
